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ABSTRACT Topical imiquimod is a medication approved for the treatment 
of external genital and perianal warts, actinic keratosis, and superficial basal 
cell carcinoma. There have also been reports of its successful use in patients 
with lentigo maligna melanoma in situ.  An 80-year-old female patient was 
diagnosed with lentigo maligna melanoma in situ which was then surgically 
removed. After several recurrences, nonsurgical treatment using topical 5% 
imiquimod was introduced. At 9-month follow-up the skin was completely 
healed with no evidence of cancer recurrence. In select cases, topical imiqui-
mod seems to be an effective alternative to surgical treatment of melanoma 
in situ (MIS). Further studies are necessary to assess the successfulness of this 
treatment method.
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INTRODUCTION
Imiquimod is a topical immunomodulator, the 
use of which has been approved for the treatment of 
external genital and perianal warts, actinic keratosis, 
and superficial basal cell carcinoma (1). A growing 
number of reports also describe its use in treatment 
of melanoma in situ (MIS) (2-4).
Lentigo maligna is the most prevalent presenta-
tion of MIS. It typically occurs on sun-exposed parts 
of the body such as the face, head, and neck usually 
in older people with 65 years as the mean age at pre-
sentation (4). If left untreated, it slowly grows over the 
course of several years with a high risk of evolving 
into an invasive melanoma termed lentigo maligna 
melanoma, which shares the same prognosis as other 
types of invasive melanoma (4-6). Current guidelines 
suggest wide excision with 5 mm margins (6,7). How-
ever, there are cases when the size or location of the 
lesion preclude a surgical approach. Radiotherapy is 
recommended in such cases. When both surgery and 
radiotherapy are not appropriate or refused, topical 
imiquimod is the recommended treatment. Cryother-
apy and laser therapy are not recommended for the 
treatment of lentigo maligna melanoma in situ (4,6). 
We present a case demonstrating the efficacy of 
topical imiquimod in the treatment of recurrent len-
tigo maligna melanoma in situ. 
CASE REPORT
An 80-year-old woman with no medical history re-
lated to dermatologic or oncological diseases visited 
the dermatologist in March 2013 with a non-raised, 
pigmented lesion on the left part of the forehead. She 
reported the lesion had grown and changed color the 
over a period of 5-7 years. The same lesion had previ-
ously been diagnosed by her general practitioner as 
senile lentigo. At presentation, the lesion measured 
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4.3×2.4 cm and had a brown pigmentation with small 
black areas (Figure 1).
After surgical consultation with the patient, a par-
tial excision under local anesthesia was performed in 
April 2013. The specimen was sent to the pathologist. 
The final pathological analysis confirmed our clinical 
diagnosis of lentigo melanoma or MIS without inten-
sive growth (Figure 2). Excision of the remaining part 
of the lesion followed in November 2013. Pathohis-
tological examination showed that the margins were 
free of tumor cells.
A follow up examination in September 2014 re-
vealed partial recurrence of the lesion, and another 
excision was performed. Pathohistological examina-
tion showed clear margins once again.
At the follow up examination in June 2018, the 
lesion was discovered to be growing again after a 
three-year remission. In October 2018, we discussed 
surgical and non-surgical options with the patient. 
Due to the patient’s advanced age and her desire to 
avoid another surgery and radiotherapy, treatment 
with 5% topical imiquimod was initiated. Imiquimod 
cream was prescribed 6 days per week once daily, fol-
lowed by a 1-day interval without treatment. After 6 
weeks of treatment the reaction was very strong, pre-
sented as an erythematous superficial ulcer covered 
with an eschar (Figure 3).
The patient was asked to cease use of imiquimod 
and instead commence daily application of a salicylic 
acid and betamethasone ointment. At the 1-week fol-
low-up visit, the inflammation had subsided and the 
scab had come off (Figure 4).
At the 2-month follow-up visit we observed com-
plete regression of the cancerous part of the lesion. 
Surrounding erythema was minimal.
At the 9-month follow-up examination the skin 
was healed. There was no evidence of lentigo malig-
na recurrence (Figure 5).
DISCUSSION
Imiquimod belongs to a class of drugs referred to 
as imidazoquinolines. It directly brings about apopto-
sis in tumor cells by facilitating an increase in caspase 
activity and up-regulating proapoptotic proteins such 
as Bax and Bak. Its indirect effect is triggered by bind-
ing to toll-like receptors on macrophages, neutrophils, 
and dendritic cells which causes an increased release 
Figure 1. Lentigo maligna melanoma on the forehead at 
the first visit at our outpatient clinic.
Figure 2. Histopathological examination revealed an in-
creased number of atypical melanocytes forming nests at 
the dermo-epidermal junction as well as melanoma cells. 
Typical picture of lentigo maligna melanoma with no inva-
sion.
Figure 3. Strong reaction after week 6 of imiquimod topical 
treatment. An erythematous superficial ulcer covered with 
an eschar.
of inflammatory cytokines, most notably interleukin 
(IL)-12, tumor necrosis factor (TNF)-alpha and inter-
feron alpha. These in turn increase the number of 
natural killer cells and cytotoxic lymphocytes which 
attack malignant cells (1). Topical use of imiquimod 
is FDA approved for the treatment of genital human 
papillomavirus, actinic keratosis, and superficial basal 
cell carcinoma (1,4,8). Studies have also reported its 
use in the treatment of lentigo melanoma (4,5). 
Current guidelines suggest surgical excision with 
5 mm margins as the mainstay treatment for lentigo 
maligna melanoma in situ (6,9). However, studies 
have shown that 5 mm margins are often inadequate. 
Kunishige et al. reported that 5 mm margins cleared 
only 86% of MIS margins, while 9 mm margins were 
successful in 98.9% of interventions (9). Another 
study showed that 5 mm margins were only sufficient 
in 42% of cases (10). In case surgery is not possible 
or is refused, radiotherapy is the treatment of choice. 
When both surgery and radiotherapy are not appro-
priate or refused, topical imiquimod is the recom-
mended treatment. Cryotherapy and laser therapy 
are not recommended for the treatment of LM (4,6). 
Histological examination of lentigo maligna mela-
noma in situ reveals the following typical features: hy-
perplasia of atypical melanocytes at the dermo-epi-
dermal junction, confluence of atypical melanocytes, 
and occasionally pagetoid spread (11). Atypical me-
lanocytes can therefore extend beyond the clinically 
obvious borders of lentigo maligna melanoma in situ. 
These atypical cells can then blend with surrounding 
sun-damaged skin, resulting in the need to increase 
margins in order to prevent local recurrences. This is 
known as the field change effect (4).
One of the earliest case reports using 5% imiqui-
mod cream to treat lentigo maligna melanoma in situ 
was published in 2000 by Ahmed and Berth-Jones. 
The patient was an 88-year-old man with a large lesion 
on the scalp that was treated for 7 months, 3 times a 
week (2,4). Treatment resulted in a complete clinical 
and histological cure. The patient was followed up for 
9 months without signs of recurrence (2).
A similar case was reported in 2012 by Ellis et al. 
After 4 surgeries with persisting positive margins, an 
82-year-old man with LM on his right cheek was treat-
ed with topical 5% imiquimod cream for 3 months. 
No clinical signs were present several months after 
the conclusion of the treatment (5).
In 2015, Fan et al. reported the case of a 75-year-
old woman with MIS on her left cheek. Nonsurgical 
treatment was proposed after 2 surgeries with per-
sisting positive margins. Imiquimod was used 5 times 
per week once daily. After a month, an erythema with 
central eschar was observed around the incision. Use 
of imiquimod was decreased to 3 times per week for 
12 weeks. At the 4-month follow-up the erythema 
had almost completely subsided. Nine months after 
treatment there was no clinical evidence of persisting 
MIS (4).
In our case, 5% imiquimod cream was applied 
for 6 days per week once daily, followed by a 1-day 
interval without treatment. This short therapy result-
ed in total disappearance of the lentigo maligna le-
sion. After a period of 9 months there was no sign of 
recurrence.  
Figure 4. Regression of the reaction to imiquimod treat-
ment due to use of betamethasone-containing ointment.
Figure 5. Complete regression of lentigo maligna mela-
noma 9 months after treatment completion. No effect on 
seborrheic keratosis. 
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Our case shows that even a shorter therapy with 
5% imiquimod can be effective and there may be no 
need for longer therapy, which can bring major dis-
comfort to the patient.
CONCLUSION
Imiquimod appears to be an effective form of 
treatment for MIS in selected cases when surgical 
options are not feasible. However, more case reports 
with longer follow-up periods may be required to 
further justify the use of immunomodulators such as 
imiquimod.
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